Biomarker and IVD pipeline
Scailyte´s clinical focus is to develop diagnostic applications from single-cell data in oncology and women´s health by using cutting-edge analytical approaches.
Establishing a precision diagnostics portfolio
Cutaneous T-cell lymphoma
First disease biomarker clinically validated: our trained AI demonstrated unprecedented accuracy in a blinded study
Cutaneous T cell lymphoma (CTCL) is a rare and severe skin cancer. In its initial stages CTCL shares similar symptoms to highly prevalent skin conditions such as atopic dermatitis (AD). Currently there is a lack of a definitive diagnostic test for CTCLs which means the disease is typically identified in advanced stages, once the patient’s immune system is compromised, or worse: altogether misdiagnosed. For the most aggressive form of CTCL, Sezary Syndrome, the 5 year survival rate is between 20–27%.
Scailyte is facing this challenge through the development of a precise and predictive diagnostic test. Using our proprietary AI driven cell analytics pipeline we identified CTCL- specific biomarkers that accurately diagnose CTCL with >90% specificity and sensitivity. This new diagnostic test will facilitate timely intervention, improve patient quality of life, dramatically reduce the treatment costs and ultimately save patient lives.